Patiromer reduced serum potassium across baseline kidney function and hyperkalemia subgroups, with greater effect in patients with reduced kidney function and baseline hyperkalemia, which suggest potential heterogeneity in potassium-lowering effects of patiromer across subgroups.
Renin-angiotensin system inhibitor (RASi) represents a cornerstone of guideline-directed medical therapy for heart failure with reduced ejection fraction (HFrEF). However, RASi is often underutilized in patients with advanced chronic kidney disease (CKD) due to concerns regarding hyperkalemia and worsening renal...
Y. Tamaki, H. Yaku, E. Yamamoto et al.· European Heart Journal· 0 citations
Elderly patients with heart failure with reduced ejection fraction (HFrEF) and chronic kidney disease (CKD) are underrepresented in clinical trials. While ACE inhibitors (ACEi) and angiotensin receptor blockers (ARB) are cornerstone therapies for HFrEF, concerns about renal deterioration lead to underuse in patie...
P. Puiu, F. Ruschitzka, A. Flammer et al.· European Heart Journal· 0 citations
BACKGROUND
Calcium channel blockers (CCBs) are frequently prescribed to manage hypertension in patients with heart failure with preserved ejection fraction (HFpEF). However, whether individual dihydropyridine agents exert uniform class effects on myocardial wall stress remains unclear.
METHODS
This retrospective, sin...
E. Harada, T. Yamada, Y. Mizuno et al.· American Journal of Hyperten...· 0 citations
Background:
Serum potassium is a known prognostic marker in patients with heart failure (HF) and chronic kidney disease (CKD), with both hypo- and hyperkalemia associated with adverse outcomes. The POTCAST trial demonstrated that targeting a potassium range of 4.5-5.0 mmol/L may be optimal in patients at high risk f...
Henri Lu, B. Claggett, G. Filippatos et al.· Circulation· 0 citations
Patients with heart failure with reduced ejection fraction (HFrEF) frequently have coexisting chronic kidney disease (CKD). Although angiotensin receptor–neprilysin inhibitors (ARNi) improve cardiovascular outcomes in HFrEF, evidence in advanced CKD is limited, particularly regarding progression to dialysis....
C. Hsu, T. N. K. N. Truong, Ching-Lin Hung· European Heart Journal· 0 citations
Older observational studies in cirrhosis and heart failure (HF) suggest that treatment with spironolactone is frequently associated with hyponatraemia, which is mechanistically plausible given the known actions of aldosterone. However, the effect of the nonsteroidal mineralocorticoid receptor antagonist (nsMRA) f...
R. Ono, K. Docherty, A. Henderson et al.· European Heart Journal· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.